

MAR 30 2007

Doc ID:

## E 510(k) Summary

K070729

**Submitter's Name:** Fall Prevention Technologies, LLC  
**Submitter's Address:** 4601 Gateway Circle  
Kettering, OH 45440  
**Submitter's Telephone:** 937-434-5455  
**Contact Name:** Frank Scarpino, PhD  
**Date Summary was Prepared:** December 10, 2006  
**Trade or Proprietary Name:** balanceback™ Mobile Intuitive VNG System  
**Common or Usual Name:** Mobile VNG  
**Classification Name:** Nystagmograph (21 CFR 882.1460), product code GWN, Class II

**Predicate Devices:**

Device Name	510(k) Number
balanceback™ Intuitive VNG System	K042529

**Indications for Use:**

The balanceback™ Mobile iVNG device is intended for recording, viewing, and analyzing eye movements in support of identifying balance disorders in human subjects. The Mobile iVNG is intended for use only by trained physicians or clinicians in an appropriate doctor's office or health care facility. This device provides no diagnoses nor does it provide diagnostic recommendations.

**Description of the Device and Summary of the Technological Characteristics:**

Eye movements have long been known to provide important clues to the identification and location of balance disorders. Physicians and other clinicians employ the VNG system to conduct a set of established, well-known and well-documented eye movement tests. The results of the VNG eye movement tests are combined with other clinical information so that the attending clinicians may render findings on the health of the patient's primary balance sensors and related balance processing system.

Using the Mobile VNG, clinicians guide patients through a series of eye movement tests. A testing battery (i.e., an *examination*) typically consists of all eight tests supported by the VNG: caloric, positional, Hallpike, gaze, saccades, smooth pursuit, optokinetic, and high-frequency head shake. The attending physician may select one, several, or all tests, and has full flexibility in determining the sequence of the tests to be performed.

The patient under examination wears the iVNG goggles. The goggles contain one IR light source and one IR camera for each eye. The IR video cameras sense the infrared signal reflected from the eyes and create a continuous monochromatic (grayscale) video motion

## 7.3

picture stream of the eyes. The infrared signal is used because the human eye cannot detect the presence of the infrared signal and therefore this illumination does not create perturbations in measurements of eye movement. Measurements may therefore be made both in the presence and in the absence of visible light, thus providing clinicians with maximum flexibility for making measurements in a wide variety of situations.

The video stream from the IR cameras is digitized and transferred into the memory of the digital computer where signal processing software tracks, records, analyzes and displays eye movements for the attending clinician. The Mobile iVNG system makes appropriate calculations and presents reports of well-known and well-documented parameters associated with each eye movement test.

Some eye tests require the patient to follow a visual stimulus. A projector, controlled by the iVNG hardware, displays stimuli on any light-colored surface, such as a wall or projection screen. The goggles and Mobile iVNG software record the patient's eye movements while he/she follows the stimulus.

**Substantial Equivalence:**

The balanceback™ Mobile iVNG device is substantially equivalent to the balanceback™ iVNG Workstation System (Desktop Configuration). This device supports the recording, viewing, and analyzing of horizontal and vertical eye movements to assist in the identification of balance disorders in human subjects. This device uses near identical technology, including the same goggles mounted with video cameras and software handling all the same tests (such as: caloric, positional, Hallpike, gaze, saccades, smooth pursuit, and optokinetic examinations). These devices use the same sampling rate and similar illumination wavelengths. The primary differences are the configuration (from desktop to laptop) and the controls of the control box (additional video management hardware).

**Testing:**

Various tests of the hardware and software are being performed to verify system specifications. Verification procedures with pass/fail criteria were developed to ensure that the product met all the specified requirements. As part of this verification, a certified body shall conduct tests to determine the conformance of the device to the recognized standards shown below. The device will not be marketed or sold until it has been certified to pass these tests.

- ANSI Z-136.1 (2000)
- IEC 60601-1 (1988) +A1 (1991) +A2 (1995)
- IEC 60601-1-1 (2000)
- IEC 60601-1-2 (2001)
- UL 60601-1 (2003)



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Fall Prevention Technologies, LLC  
% Intertek Testing Services  
Mr. Neil E. Devine, Jr.  
2307 East Aurora Road, Unit B7  
Twinsburg, Ohio 44087

MAR 30 2007

Re: K070729

Trade/Device Name: balanceback™ Mobile Intuitive VNG System  
Regulation Number: 21 CFR 882.1460  
Regulation Name: Nystagmograph  
Regulatory Class: II  
Product Code: GWN  
Dated: February 14, 2007  
Received: March 15, 2007

Dear Mr. Devine:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Mr. Neil E. Devine, Jr.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Mark N. Melkerson', with a long horizontal flourish extending to the right.

Mark N. Melkerson  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

**D Indications for Use Statement****Indications for Use**

510(k) Number (if known):

K070729

Device Name:

balanceback™ Mobile Intuitive VNG System**Indications for Use:**

The balanceback™ Mobile Intuitive VNG device is intended for recording, viewing, and analyzing eye movements in support of identifying balance disorders in human subjects. The Mobile iVNG is intended for use only by trained physicians or clinicians in an appropriate doctor's office or health care facility. This device provides no diagnoses nor does it provide diagnostic recommendations.


Prescription Use  
(Part 21 CFR 801 Subpart  
D)Yes

AND/OR

Over-The-Counter-Use  
(Part 21 CFR 801 Subpart  
C)No

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE  
IS NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)  
Division of General, Restorative,  
and Neurological Devices

K070729